ScreenerHero

0IL8Kyntra Bio, Inc.

LSE · GB · Healthcare · Biotechnology · kyntrabio.com
7.521USD+6.11%Mkt Cap: —P/E: —

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting C…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap—
Enterprise Value-39.31M $
Revenue (TTM)4.62M $
Gross Profit-22.57M $
Net Income (TTM)-30.91M $
Revenue/Share1.141 USD
Last Price7.521 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.79
EV/Revenue-8.52
P/S—
P/B-1.00
EPS (TTM)-3.04
EPS (Forward)—
52W Range
6.810100% of range7.521
52W High7.521 USD
52W Low6.810 USD
Profitability
Gross Margin0.00%
Oper. Margin1191.52%
EBITDA Margin0.00%
Profit Margin3968.63%
ROE—
ROA-22.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.05M $
CapEx (TTM)—
FCF Margin1171.46%
FCF Yield—
Net Debt-91.32M $
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity—
Current Ratio2.69
Quick Ratio2.54
Book Value/Sh-7.4450 USD
Cash/Share22.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.04:1
Split DateJun 17, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.84.98M
Float3.56M
Insiders2.02%
Institutions24.68%
Technical
SMA 501.582 (+375.4%)
SMA 2002.791 (+169.5%)
Beta1.04
S&P 52W Chg19.18%
Avg Vol (30d)1.11K
Avg Vol (10d)27.00K
Technical Indicators
RSI (14)56.1
MACD0.0359
MACD Signal0.0727
MACD Hist.-0.0368
BB Upper7.851 USD
BB Middle7.395 USD
BB Lower6.938 USD
BB Width12.35%
ATR (14)0.3229 USD
Vol Ratio (20d)1.89x